Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PTCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PTCT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

PTC Therapeutics Inc

PTCT
Current price
47.98 USD -0.95 USD (-1.94%)
Last closed 49.07 USD
ISIN US69366J2006
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 889 140 992 USD
Yield for 12 month +51.21 %
1Y
3Y
5Y
10Y
15Y
PTCT
21.11.2021 - 28.11.2021

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey. Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

62.81 USD

P/E Ratio

7.54

Dividend Yield

Financials PTCT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PTCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+806 780 000 USD

Last Year

+937 822 000 USD

Current Quarter

+1 176 096 000 USD

Last Quarter

+213 172 000 USD

Current Year

+749 382 000 USD

Last Year

+872 336 000 USD

Current Quarter

+1 163 234 000 USD

Last Quarter

+193 582 000 USD
EBITDA 895 796 992 USD
Operating Margin TTM 82.43 %
Price to Earnings 7.54
Return On Assets TTM 24.42 %
PEG Ratio 0.81
Return On Equity TTM -7 740.12 %
Wall Street Target Price 62.81 USD
Revenue TTM 1 772 758 016 USD
Book Value -2.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 459.70 %
Dividend Yield
Gross Profit TTM 1 189 913 984 USD
Earnings per share 6.51 USD
Diluted Eps TTM 6.51 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 33.56 %

Stock Valuation PTCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 7.54
Forward PE 6.10
Enterprise Value Revenue 1.27
Price Sales TTM 2.19
Enterprise Value EBITDA 2.69
Price Book MRQ 1 743.27

Technical Indicators PTCT

For 52 Weeks

29.02 USD 58.38 USD
50 Day MA 48.27 USD
Shares Short Prior Month 4 751 620
200 Day MA 46.04 USD
Short Ratio 5.01
Shares Short 5 072 028
Short Percent 7.36 %